Posted by Gary Schwitzer in Drug industry
Physician-blogger Elaine Schattner writes that Gregg of the Allman Brothers has hepatitis C and has “teamed with” or is “working with” Merck to promote hep C awareness.
“The ethics of this are complicated: On the one hand, it might be a good thing for a music icon to raise public awareness about hepatitis C, so that more people at risk might get tested and then treated early before they develop severe liver disease and cancer, and would feel better. Gregg Allman is in a position to spread that message effectively: “If I have hep C, you might have hep C. Let me tell you about it…” (somewhat in the style of Magic Johnson, on HIV).
On the other hand, the notion of a post-transplant musician serving as the public’s primary source for information on hepatitis C seems preposterous, especially if he’s tied in with a pharmaceutical company with a stake in the matter. The situation is reminiscent of Sally Fields starring in commercials for Boniva, an osteoporosis drug.
You might ask yourself — and it’s not a trivial exercise — who can best, and objectively, inform the public about viral liver infections and the potential benefits of treatment: doctors? (we harbor biases; many have industry ties); patient peers? (Allman is a heightened example, but he’s hardly objective about this, either)”
Oh, and were you aware that Merck is in a heated battle with competition in the multibillion dollar hepatitis C drug market?